Vision Capital Management’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$276K Sell
1,982
-45
-2% -$6.3K 0.03% 126
2025
Q4
$249K Sell
2,027
-315
-13% -$38.3K 0.03% 131
2025
Q3
$260K Sell
2,342
-3,665
-61% -$417K 0.03% 128
2025
Q2
$666K Buy
6,007
+346
+6% +$36.8K 0.09% 87
2025
Q1
$634K Sell
5,661
-458
-7% -$47.3K 0.09% 89
2024
Q4
$565K Sell
6,119
-4,789
-44% -$431K 0.08% 88
2024
Q3
$915K Buy
10,908
+8
+0.1% +$610 0.13% 80
2024
Q2
$748K Buy
10,900
+64
+0.6% +$4.27K 0.11% 80
2024
Q1
$794K Buy
10,836
+173
+2% +$13.3K 0.12% 79
2023
Q4
$864K Sell
10,663
-183
-2% -$14.2K 0.13% 79
2023
Q3
$813K Sell
10,846
-166
-2% -$12.8K 0.15% 70
2023
Q2
$849K Sell
11,012
-393
-3% -$31.3K 0.14% 72
2023
Q1
$946K Sell
11,405
-400
-3% -$33.1K 0.17% 72
2022
Q4
$1.01M Sell
11,805
-149
-1% -$11.8K 0.19% 72
2022
Q3
$737K Sell
11,954
-3,820
-24% -$241K 0.15% 71
2022
Q2
$975K Sell
15,774
-3,051
-16% -$189K 0.18% 71
2022
Q1
$1.12M Buy
18,825
+1,050
+6% +$67.1K 0.18% 75
2021
Q4
$1.29M Buy
17,775
+54
+0.3% +$3.72K 0.19% 74
2021
Q3
$1.24M Buy
17,721
+421
+2% +$29.6K 0.2% 70
2021
Q2
$1.19M Buy
17,300
+3,394
+24% +$227K 0.2% 72
2021
Q1
$899K Buy
13,906
+388
+3% +$25K 0.16% 75
2020
Q4
$788K Buy
13,518
+7,147
+112% +$431K 0.15% 76
2020
Q3
$403K Buy
6,371
+77
+1% +$5.34K 0.08% 79
2020
Q2
$484K Sell
6,294
-2,048
-25% -$157K 0.11% 76
2020
Q1
$624K Buy
8,342
+1,939
+30% +$134K 0.17% 65
2019
Q4
$416K Sell
6,403
-438
-6% -$28.5K 0.1% 71
2019
Q3
$434K Sell
6,841
-36,856
-84% -$2.41M 0.11% 69
2019
Q2
$2.95M Buy
43,697
+41
+0.1% +$2.7K 0.77% 39
2019
Q1
$2.84M Buy
43,656
+3,866
+10% +$257K 0.79% 39
2018
Q4
$2.49M Sell
39,790
-12,285
-24% -$859K 0.78% 45
2018
Q3
$4.02M Buy
52,075
+223
+0.4% +$16.8K 1.09% 33
2018
Q2
$3.67M Sell
51,852
-798
-2% -$56.4K 1.07% 37
2018
Q1
$3.97M Sell
52,650
-2,418
-4% -$192K 1.17% 30
2017
Q4
$3.94M Sell
55,068
-3,067
-5% -$233K 1.15% 31
2017
Q3
$4.71M Sell
58,135
-1,912
-3% -$146K 1.5% 19
2017
Q2
$4.25M Sell
60,047
-1,449
-2% -$96.4K 1.46% 23
2017
Q1
$4.18M Sell
61,496
-1,514
-2% -$106K 1.5% 23
2016
Q4
$4.51M Buy
63,010
+8,264
+15% +$614K 1.76% 20
2016
Q3
$4.33M Sell
54,746
-1,457
-3% -$118K 1.82% 19
2016
Q2
$4.69M Sell
56,203
-67,703
-55% -$6.01M 1.99% 15
2016
Q1
$11.4M Buy
123,906
+3,269
+3% +$295K 2.78% 5
2015
Q4
$12.2M Sell
120,637
-39,321
-25% -$4.09M 2.8% 5
2015
Q3
$15.7M Buy
159,958
+7,809
+5% +$867K 3.51% 4
2015
Q2
$17.8M Sell
152,149
-55,662
-27% -$6.08M 3.32% 5
2015
Q1
$20.4M Sell
207,811
-71,111
-25% -$7.22M 3.05% 5
2014
Q4
$26.3M Buy
278,922
+12,197
+5% +$1.26M 3.03% 5
2014
Q3
$28.4M Sell
266,725
-49,754
-16% -$4.87M 3.53% 1
2014
Q2
$26.2M Sell
316,479
-34,280
-10% -$2.67M 3.13% 2
2014
Q1
$24.9M Buy
350,759
+12,268
+4% +$962K 3.03% 4
2013
Q4
$25.4M Sell
338,491
-28,617
-8% -$1.99M 3.02% 4
2013
Q3
$23.1M Buy
367,108
+81,632
+29% +$4.88M 2.73% 4
2013
Q2
$14.6M Buy
+285,476
New +$14.9M 2.35% 28

Other funds holding GILD

Vision Capital Management's GILD Position: Q1 2026 in Review

Vision Capital Management reduced its Gilead Sciences (GILD) stake by 2.2% in Q1 2026, selling an estimated $6.3K and leaving 1,982 shares worth $276K. The position accounts for 0.03% of the portfolio, ranked #126.

Vision Capital Management first reported a position in GILD in Q2 2013 and has held it in 52 quarters since. The position peaked at $28.4M in Q3 2014. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

  • Vision Capital Management held 1,982 shares of Gilead Sciences worth $276K as of Q1 2026.
  • Vision Capital Management sold 45 Gilead Sciences shares in Q1 2026, an estimated $6.3K.
  • Gilead Sciences made up 0.03% of Vision Capital Management's portfolio in Q1 2026, its #126 holding.
  • Vision Capital Management first reported a position in Gilead Sciences in Q2 2013 and has held it in 52 quarters since.
  • Vision Capital Management's Gilead Sciences position peaked at $28.4M in Q3 2014.
  • 2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Vision Capital Management's 13F filing for Q1 2026, filed 24 Apr 2026.